The largest database of trusted experimental protocols

Vitek 2 compact automatic system

Manufactured by bioMérieux
Sourced in France

The VITEK 2 COMPACT® is an automated microbiology system designed for bacterial identification and antimicrobial susceptibility testing. The system utilizes advanced technology to streamline the workflow in clinical microbiology laboratories.

Automatically generated - may contain errors

Lab products found in correlation

5 protocols using vitek 2 compact automatic system

1

Antibiotic Resistance Profiling of A. baumannii

Check if the same lab product or an alternative is used in the 5 most similar protocols
The clinical isolates used in this study were collected from June 2014 to January 2015 as different kinds of specimen sample types, including sputum, urine, abscess secretion, blood, hydrothorax, and ascites, from infected patients who visited the Third Xiangya Hospital of Central South University, P.R. China, a three A‐level large‐scale comprehensive teaching hospital with 2,200 beds. Bacterial strains were primarily identified as A. baumannii complex by VITEK 2 COMPACT® automatic system (bioMérieux). Bacterial cultures were preserved in bacterial magnetic bead cryopreservation tubes, maintained at −80°C, and subcultured on blood agar plates overnight to obtain monoclonal colonies at 37°C before each experimental assay. The antibiotic susceptibility of all strains was evaluated using the VITEK 2 COMPACT® automatic system and determined according to Clinical and Laboratory Standards Institute procedures (Clinical & Laboratory Standards Institute, 2014). Pseudomonas aeruginosa ATCC 27853 and Staphylococcus aureus ATCC 27923 served as quality controls for the susceptibility test.
+ Open protocol
+ Expand
2

Multidrug-Resistant A. baumannii Isolates

Check if the same lab product or an alternative is used in the 5 most similar protocols
A collection of 61 non-repetitive (1 per patient) carbapenem-resistant (imipenem and meropenem) and aminoglycoside-nonsusceptible (amikacin, gentamicin, and tobramycin) A. baumannii strains were isolated in 2009 (n=27), 2010 (n=20), and 2011 (n=14), respectively, from patients hospitalized in the Specialized Hospital in Cracow, Poland. The isolates were identified as A. baumannii by the Vitek 2 Compact automatic system (bioMérieux, Poland) and PCR amplification of the blaOXA-51-like gene. Most tested isolates originated from Intensive Care Unit patients (36; 59.0%) and Burn Therapy Unit patients (18; 29.5%). The isolates were recovered from various clinical specimens including: (in descending frequency) respiratory tract samples (30; 49.2%), wound swabs (13; 21.3%), urine (9; 14.8%), blood (6; 9.8%), and other specimens (3; 4.9%). While phenotypic identification and antibiotic susceptibility testing, as well as molecular detection of blaOXA-51-like, blaOXA-23-like, blaOXA-40-like, and blaOXA-58-like genes, among 27 and 20 strains recovered in 2009 and 2010, respectively were described previously [13 (link)], 14 additional isolates derived from the Specialized Hospital in Cracow, Poland in 2011 were examined in the current study.
+ Open protocol
+ Expand
3

Vancomycin Pharmacokinetics in Meningitis

Check if the same lab product or an alternative is used in the 5 most similar protocols
All patients received I.V. vancomycin (Vancocin, Vianex S.A.) alone or in combination with meropenem. Vancomycin was administrated I.V. 1,000 mg every 12 h (0.9% NaCl 250 ml dilution, continuous infused 2 h with a syringe pump) as the recommended daily dose for adult patients with normal renal function. No patients received corticosteroids during anti-infection treatment. Samples of blood and CSF were collected at the fifth dose (day 3). At least 2 ml of venous blood and 2 ml of CSF were collected 0.5 h before the start of infusion of vancomycin, and 1, 2, 3, and 8 h from the start of infusion. CSF samples were obtained by a temporary lumbar catheterization. About 2 ml of CSF remaining in the drainage tube was discarded, and 2 ml of fresh CSF was collected. The blood and CSF samples were collected using normal biochemical test tubes.
At the fifth CSF collection, appropriate amount of CSF was collected for CSF biochemical analysis, cytological analysis, PCT analysis, and microbial culture. Bacteriological antibiotic sensitivity test was determined using the Vitek-2 Compact automatic system (Biomerieux Inc., France). The temporary lumbar tube was removed or retained according to treatment needs after the collection of CSF samples.
+ Open protocol
+ Expand
4

Carbapenem-Resistant Klebsiella pneumoniae Detection

Check if the same lab product or an alternative is used in the 5 most similar protocols
All isolates identification and antibiotic susceptibility tests were performed using the same VITEK 2 compact automatic system (bioMérieux, Marcy-l’Étoile, France). When K. pneumoniae was repeatedly detected in the same patient, only the data of the first positive result was recorded for statistical analysis. CRKP was determined by measuring the minimum inhibitory concentration (MIC) using E-test strips (AB Biodisk, Solna, Sweden). Carbapenem resistance was defined as an ertapenem MIC ≥ 2 μg/mL and meropenem and/or imipenem MIC ≥ 4 μg/mL.19 (link) Intermediate susceptibility was classified as resistant.
+ Open protocol
+ Expand
5

Antimicrobial Susceptibility of Aeromonas

Check if the same lab product or an alternative is used in the 5 most similar protocols
The antimicrobial susceptibility of 69 Aeromonas isolates identified at the species level was determined by VITEK2 Compact Automatic System (bioMerieux, France) using AST-N331 cards containing the following fluoroquinolones: ciprofloxacin and levofloxacin. The bacterial colony suspension equivalent to 0.5 McFarland was diluted in 0.45% saline into 1.5 × 107 CFU/ml, according to the manufacturer’s procedure. The results for Aeromonas spp. were interpreted on the basis of minimum inhibitory concentration (MIC) cutoff values according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2021 recommendation and Clinical and Laboratory Standards Institute (CLSI) guideline M45 (CLSI, 2015 ; CLSI, 2019 ). On the basis of expert rules, Pseudomonas aeruginosa ATCC 27853 (CLSI, 2015 ; EUCAST, 2021 ) and Escherichia coli ATCC 25922 were used as quality control. Additionally, A. veronii DSM 7386 (Deutsche Sammlung von Mikroorganismen, Leibniz-Institut, Germany) was used as positive control.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!